Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units.

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myelogenous Leukemia

Conditions

Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease

Trial Timeline

Aug 1, 2013 โ†’ May 5, 2017

About Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units.

Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units. is a phase 3 stage product being developed by Mesoblast for Acute Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01854567. Target conditions include Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01854567Phase 3Completed

Competing Products

20 competing products in Acute Myelogenous Leukemia

See all competitors